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Abstract. The exact phenotype of human periodontal ligament 
cells (hPDLCs) remains a controversial area. Basic fibroblast 
growth factor (FGF‑2) exhibits various functions and its effect 
on hPDLCs is also controversial. Therefore, the present study 
examined the effect of FGF‑2 on the growth and osteoblastic 
phenotype of hPDLCs with or without osteogenic inducers 
(dexamethasone and β-glycerophosphate). FGF-2 was added 
to defined growth culture medium and osteogenic inductive 
culture medium. Cell proliferation, osteogenic differentiation 
and mineralization were measured. The selected differentiation 
markers, Runx2, collagen type Ⅰ, α1 (Col1a1), osteocalcin (OCN) 






expression of Runx2, OCN and EGFR, but suppressed Col1a1 
gene expression in the absence of osteogenic inducers, whereas 
all these gene levels had no clear trend in their presence. The 
Runx2 protein expression was clearly increased, but the OCN 
protein level showed no evident trend. The mineralization 
assay demonstrated that FGF‑2 inhibited mineralized matrix 
deposition with osteogenic inducers. These results suggested 
that FGF-2 induces the growth of immature hPDLCs, which 
is  a  competitive  inhibitor  of  epithelial  downgrowth,  and 
suppresses  their differentiation  into mineralized  tissue by 
affecting Runx2 expression. Therefore, this may lead to the 
acceleration of periodontal regeneration.
Introduction
Periodontitis is a highly prevalent inflammatory oral disease. 
Delayed treatment for aggressive periodontitis could result 
in the loss of soft connective tissues and bone that surrounds 
the teeth and is a major cause of tooth loss in adults (1). The 
ideal aim of periodontal therapy is achieving simultaneous 
regeneration of the lost alveolar bone, cementum and peri-
odontal soft tissues (2). Current treatment options, such as 
professional tooth cleaning/scaling/polishing, root planning, 
periodontal debridement and guided tissue regeneration, used 
either alone or in combination, only have a limited success in 
impeding periodontitis, particularly at the advanced stage of 
the disease (2-4). Together with the recent advances in peri-
odontal tissue engineering, novel treatment methods utilizing 
signaling molecules and/or cell‑based  therapies have been 
developed as new strategies to regenerate periodontal tissue 
damaged by periodontitis (2,5,6).
Human periodontal ligament cells (hPDLCs) are believed 




studies indicate that the organic osteogenic inductive factors, 
dexamethasone (DEX) and β-glycerophosphate (β-GP), 
are efficient for stimulating human osteoblasts (HOBs) and 
mesenchymal stem cells (MSCs) in vitro, but are not believed 
to be able to achieve similar stimulation in vivo. Additionally, 
the exact phenotype of hPDLCs remains a topic of contro-
versy, in particular, concerning whether these cells are similar 
to a  terminally differentiated cell  type with a  fibroblastic 
nature or a progenitor cell  that potentially can be  induced 
FGF-2 induces the proliferation of human periodontal ligament 
cells and modulates their osteoblastic phenotype by affecting Runx2 
expression in the presence and absence of osteogenic inducers
SHAOFENG AN1,  XIANGYA HUANG1,  YAN GAO1,  JUNQI LING1,  YIHUA HUANG1  and  YIN XIAO2
1Department of Operative Dentistry and Endodontics, Guanghua School of Stomatology, Hospital of Stomatology, 
Sun Yat‑sen University and Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, 





tive Dentistry and Endodontics, Guanghua School of Stomatology, 
Hospital of Stomatology, Sun Yat-sen University and Guangdong 
Provincial  Key  Laboratory  of  Stomatology,  56  Ling  Yuan  Road 
West, Guangzhou, Guangdong 510055, P.R. China
E‑mail: lingjq@mail.sysu.edu.cn
Professor Yin Xiao, Institute of Health and Biomedical Innovation, 
Queensland University of Technology, 60 Musk Ave, Kelvin Grove 
Campus, Brisbane, QLD 4059, Australia
E‑mail: yin.xiao@qut.edu.au
Key words:  basic  fibroblast  growth  factor‑2,  human  periodontal 
ligament cells, osteogenic inducers, osteogenic differentiation, 
epithelial differentiation








associated with periodontal tissue regeneration (12-14).
The optimum aims of periodontal treatment are to regen-
erate the destroyed cementum, alveolar bone and periodontal 
ligament, while also preventing epithelization during wound 
healing (2,15,16). Numerous studies have demonstrated that 
the topical application of FGF-2 promotes the healing of 
destructive periodontal tissue without ankylosis, root resorp-
tion or epithelial downgrowth in experimental alveolar 
bone defects in the beagle dog and primate models (16‑22). 
However, FGF-2 is considered a multifunctional growth factor 
that has diversified actions and its effect in the differentiation 
of hPDLCs remains controversial (12). hPDLCs are a hetero-
geneous population of cells and the exact function of FGF-2 
in  stabilizing  the  fibroblastic  phenotype  and maintaining 
the human periodontal ligament (hPDL) structural integrity 
remains largely unknown. Based on the above factors and our 
previous study (23), we hypothesize that in the present experi-
mental system (with or without osteogenic inducers), FGF-2 
may be able to maintain the fibroblastic phenotype of hPDLCs 
and prevent them from differentiating into mature osteoblasts.








Cell culture. hPDLCs were isolated from healthy premolar 
teeth  using  a  previously  described method  (23).  Healthy 
subjects <20 years old undergoing orthodontic treatment were 
recruited with the understanding and consent for the isola-
tion of hPDLCs. All the experimental protocols used were 
approved by the Ethics Committee of Sun Yat‑sen University 
(Guangdong, China). Briefly, fresh PDL tissues were collected 
rapidly following the tooth extraction. Under sterile conditions, 
the PDL tissue was washed with sterile phosphate‑buffered 
saline (PBS) and scraped from the middle-third of the root 
with a  scalpel. The  tissue was  subsequently  chopped  into 
smaller  pieces  and  soaked  in  fresh Dulbecco's modified 
Eagle's medium [DMEM/high glucose; Hyclone Biochemical 
Product (Beijing) Co., Ltd., Beijing, China] containing 
20% fetal bovine serum (FBS) (Biological Industries Israel 
Beit‑Haemek, Ltd., Kibbutz Beit‑Haemek,  Israel)  and 2% 
(v/v) penicillin/streptomycin (Invitrogen Life Technologies, 
Carlsbad, CA, USA). An explant culture method was used in 
the primary culture. The medium was changed every 3 days. 
Cells typically emerged from the tissues within 1-2 weeks 
of being explanted in a humidified atmosphere of 5% CO2 
at 37˚C. When the cells growing from the explants reached 
~80% confluency, they were subcultured at a 1:3 ratio through 
trypsinization (trypsin/EDTA; Invitrogen Life Technologies). 
Only the fifth passage of hPDLCs was used in subsequent 
experiments.
FGF‑2 treatment. Recombinant Human FGF‑basic (FGF-2) 
(Peprotech, Inc., Rocky Hill, NJ, USA) was added to the defined 
growth culture medium and osteogenic inductive culture 
medium. There were four treatment groups: ⅰ) hPDLCs + growth 
medium (GM) (DMEM containing 10% FBS and 2% peni-
cillin/streptomycin); ⅱ) hPDLCs + GM + 20 ng/ml FGF-2 
(GM + FGF-2); ⅲ) hPDLCs + osteogenic medium (OM) 
[DMEM with 10% FBS, 2% (v/v) penicillin/streptomycin, 
10‑8 M DEX, 50 µg/ml ascorbic acid and 8 mM β-GP]; and 
ⅳ) hPDLCs + OM + 20 ng/ml FGF-2 (OM + FGF-2).
Cell proliferation assay. hPDLC viability was monitored 
using a Cell Counting kit‑8 (CCK‑8) (Beyotime, Shanghai, 
China). Briefly, hPDLCs at passage 5 were seeded in 96‑well 
plates at an initial density of 3x103 cells/well in medium, with 
five replicates for each group. The medium was replaced every 
3 days. After 1, 2, 3, 5 and 7 days of subculture in medium 
treated differently, 20 µl of CCK‑8 solution was added to every 
well and incubated with the cells for 4 h in a humidified atmo-
sphere of 5% CO2 at 37˚C. The absorbance of each sample was 
determined at the wavelength of 450 nm on a 96‑well plate 
reader.
Alkaline phosphatase (ALP) activity assay. hPDLCs 
were seeded in 24-well plates in triplicate at a density of 
2x104 cells/well and cultured  in defined media subsequent 
to reaching ~80% confluency. Following 3, 7, 14 and 21 days 
in culture, an ALP activity assay kit (Nanjing Jiancheng 





Triton X-100 was added to the culture well, and the mixture 
was lysed through two freeze (-20˚C)/thaw cycles. The super-
natant (50 µl/well) was placed into 24-well plates for the ALP 
activity assay using 50 µl of an ALP substrate solution (16 mM 
p-nitrophenyl phosphate and 2 mM MgCl2). After a 30‑min 
incubation at 37˚C, the reaction was stopped by the addition 
of 50 µl of 0.2 M NaOH, and the absorbance of the reaction 
product (p-nitrophenol) was read at 520 nm.
Reverse transcription‑quantitative polymerase chain reac‑
tion (RT‑qPCR) analysis. After 7 and 14 days of culture, the 
expression levels of selected osteoblastic and fibroblastic genes 
were determined in triplicate by RT‑qPCR. Total RNA was 
extracted from hPDLCs using TRIzol Reagent (Invitrogen Life 
Technologies) and was quantified in a spectrophotometer by 
absorbance readings at 260 nm. The extracted total RNA (2 µg) 
was treated with 1 unit DNase Ⅰ for cDNA synthesis in each 
RT‑qPCR using the RevertAid™ First Strand cDNA Synthesis 
kit (K1622; MBI Fermentas, Inc., Burlington, ON, Canada). 
PCR was carried out using a combination of 2.5 µl of diluted 
cDNA and 12.5 µl of SYBR-Green Real-time PCR Master 
mix (QPK‑201; Toyobo Co., Ltd., Osaka, Japan) in a Chromo4 
System (Bio‑Rad, Hercules, CA, USA). The sequential reaction 
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conditions were as follows: 95˚C for 1 min denaturation followed 
by 40 cycles of denaturation at 95˚C for 15 sec, annealing at 
60˚C for 15 sec and extension at 72˚C for 30 sec. The specificity 
of the PCR products was confirmed by melting curve analysis 
(60-93˚C, read every 0.4˚C, hold 1 sec). GAPDH was used as 
the reference gene for data normalization. The number of cDNA 
copies was calculated with the apparent cycle threshold (CT). 
The ∆CT value expresses the difference between the CT of 
the target gene and the CT of GAPDH from the same sample: 
∆CT = the target gene CT ‑ GAPDH CT, which can be expressed 




Western blotting. After 7 and 14 days of culture, Runx2 and 
osteocalcin (OCN) protein expression was measured using 
western blotting. In brief, hPDLCs were washed three times 
with  pre‑cooling  PBS. The  constructs were  subsequently 
homogenized in sodium dodecyl sulfate polyacrylamide gel 
electrophoresis  (SDS‑PAGE)  sample  buffer,  and  cellular 
protein was extracted in lysis buffer [50 mM Tris‑HCl, 0.5% 
Triton X-100, 2 mM EDTA and 150 mM NaCl (pH 7.5)] 
containing phenylmethylsulfonyl fluoride. The protein samples 
(30 µg) were electrophoresed through 10% SDS-PAGE and 
transferred to a polyvinylidene fluoride (PVDF) membrane 
(Millipore, Bedford, MA, USA) in a wet blotting apparatus 
for 1.5 h at 300 mA. The PVDF membrane was subsequently 
blocked with  5%  bovine  serum  albumin (Wuhan Boster 
Biological Technology, Ltd., Hubei, China) for 1 h at room 
temperature, and the blot was incubated with 1:1,000 dilu-
tion of anti-human Runx2 antibody (Cat. no. AF2006; R&D 
Systems, Minneapolis, MN, USA) and 1:500 of anti-human 
OCN (Cat. no. ab10911; Millipore, Billerica, MA, USA) for 
2 h, washed with Tris‑buffered saline Tween 20 (TBST) four 
times and incubated with a 1:2,500 dilution of horseradish 
peroxidase  (HRP) AffiniPure  goat  anti‑rabbit  secondary 
antibody (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) 
for 1 h, and further washed four times with TBST. HRP detec-
tion was accomplished via chemical luminescence exposed to 
X‑ray film with an ECL western blotting detection system.
Calcium content quantitative assay. The calcium content of 
the cells was measured by a colorimetric quantitative method 
using a Calcium Assay kit (Shanghai Genmed Gene Pharma-
ceutical Technology Co., Ltd., Shanghai, China) following 
the manufacturer's instructions. Cells were seeded at a cell 
density of 5x104 cells/well in 12-well tissue culture plates. 
After 14 and 21 days of culture, deposition of calcium in the 
cell layer was performed in triplicate. The absorbances of dyes 
were read at a wavelength of 595 nm using a UV/Visible light 
Spectrophotometer (Varian Cary 50; Varian Australia Pty, 
Ltd., Mulgrave, VIC, Australia).
Alizarin Red S staining. After 7, 14 and 21 days of culture, the 
mineralized matrix nodules were detected using an Alizarin 
Red S Staining kit (Shanghai Genmed Gene Pharmaceutical 
Technology Co., Ltd.) following the manufacturer's instruc-
tions. Prior to staining, the cell cultures were washed five times 
with 10 mM sterile PBS and fixed using 10% (v/v) neutral 
buffered formalin for 30 min. Subsequently, the samples were 
stained for 5 min and the excess stain was rinsed with PBS. An 
Inverted Phase Contrast Microscope (Olympus IX41; Olympus 
Corp., Tokyo, Japan) was used to observe the stained cells.
Statistical analysis. All the values are reported as the 
mean ± standard deviation. Statistical analysis of the data was 
performed using the SPSS 17.0 software package (SPSS, Inc., 





FGF‑2 promotes the proliferation of hPDLCs. At days 1 and 2, 
FGF-2 had no significant effect on the cell proliferation 
rate  (P>0.05).  From day  3  onwards,  hPDLCs  cultured  in 
the GM with added FGF‑2 exhibited the maximal levels of 
proliferation, and those in the OM exhibited minimum levels 
(P<0.05) (Fig. 1). This suggested that supplementing growth 
media with FGF-2 enhanced proliferation of hPDLCs in the 
presence and absence of osteogenic inducers.
FGF‑2 does not affect ALP activity. The specific ALP activity 
progressively increased with the duration of culture time in 
all the groups. At days 3 and 7 of culture, FGF‑2 inhibited 
the ALP activity. However, FGF-2 promoted the ALP activity 
at days 14 and 21. There were, however, no significant differ-
ences between FGF‑2‑treated and ‑untreated groups at any 
time-points (P>0.05) (Fig. 2).
FGF‑2 affects the mRNA and protein expression of Runx2, but 
not the OCN protein level. In the cultures without osteogenic 
inducers, Runx2 mRNA expression was significantly upregu-
lated under the stimulation of FGF‑2 at days 7 and 14 (P<0.05). 
However, in the OM, there was no evident effect on Runx2 
expression (P>0.05) (Fig. 3A).
In  the  western  blot  analysis,  Runx2  expression  was 











EGFR F: GGAGAACTGCCAGAAACTGACC 106
 R: GCCTGCAGCACACTGGTTG
RT‑qPCR,  reverse  transcription‑quantitative  polymerase  chain  reaction;  bp, 
base pairs; Col1a1, collagen type Ⅰ, α1; OCN, osteocalcin; EGFR, epidermal 
growth factor receptor; F, forward; R, reverse.
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inducers under the stimulation of FGF-2. In the OM samples, 
there was no increase in Runx2 protein levels at day 7, whereas 
at day 14 there was a significantly increased protein expression 
stimulated by FGF-2 (Fig. 4A). However, the protein expression 
of OCN showed no evident changes at day 7 and 14 (Fig. 4B).
FGF‑2 affects collagen type Ⅰ, α1 (Col1a1), OCN and epidermal 
growth factor receptor (EGFR) gene expression of hPDLCs in 
the absence of osteogenic inducers. There was a significant 
decrease in Col1a1 mRNA levels in the GM + FGF-2 samples 
(P<0.05), whereas  in  the OM samples  the gene expression 
was downregulated at day 7 (P>0.05) under the stimulation of 
FGF‑2 (Fig. 3B). OCN and EGFR expression was upregulated 
in GM +  FGF‑2  (P<0.05);  but  downregulated  to  various 
degrees in the OM + FGF‑2 samples (P>0.05) (Fig. 3C and D). 
Compared with the GM condition, OM culture stimulated 
OCN and EGFR expression in the absence of FGF‑2.
FGF‑2 suppresses the mineralization of hPDLCs in the pres‑
ence of osteogenic inducers. After 14 and 21 days of culture, 
the calcium content in the cultures was measured. The calcium 
content in the FGF-2-treated groups was higher than the 
non-FGF-2 groups (P>0.05). However, in the OM + FGF-2 
group there was a significant reduction of the calcium content 
(P<0.05) (Fig. 5A).
Alizarin Red S staining indicated that mineralized nodes 
were observed only in the OM, and mineralized matrix depo-
sition gradually increased with time in culture. The addition of 
FGF-2 resulted in reduced calcium deposition as evaluated at 
days 7, 14 and 21 (Fig. 5B).
Discussion
Cell proliferation and differentiation are two crucial aspects of 
cell‑based bone regeneration. Osteogenic‑differentiated cells 
generally exhibit low proliferation rates (24) and may explain 
why hPDLCs cultured in medium with added osteogenic 
inducers exhibited the lowest proliferation rate. hPDLCs in 
groups without osteogenic inducers had higher EGFR mRNA 
levels, which resulted in increased cell proliferation most 
possibly via activation of its downstream targets, ERK1/2 and 
Akt (25,26). Thus, the cell proliferation rates in this group are 
higher compared to the OM group. CCK‑8 analysis indica ted 
that  FGF‑2 was  able  to  increase  the  proliferation  rate  of 
hPDLCs in the presence and absence of osteogenic inducers. 
These results are similar to those of a study that identified that 




and presence of osteogenic inducers. *P<0.05 against the control. (B) Representative images of the growth of hPDLCs on day 7. The GM + FGF‑2 group had 
the largest number of cells. Mineralization nodes (the white dots) appeared in the OM and OM + FGF‑2 groups (original magnification, x200).





medium (OM)]. However, FGF-2 promoted ALP activity at days 14 and 21, 
however, there were no significant differences at any time‑points.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  46:  705-711,  2015 709
FGF‑2‑induced periodontal  ligament cell proliferation, but 
inhibited FGF‑2‑induced proliferation of gingival epithelial 
cells (27). We speculate that this enhancement could provide 
an alternate route to limit the downgrowth of junctional epithe-
lium and increase the relatively low number of cells adhering 
to the scaffold surface in periodontal tissue engineering.
ALP activity was a well‑defined marker for osteogenic 
differentiation. Previous studies indicate that the addition 
of FGF‑2 significantly decreased ALP activity and calcified 
nodule formation in hPDLCs in a dose-dependent manner (12). 
The concentration of FGF-2 chosen in the present study at 
20 ng/ml was based on the previous studies (28,29). In these 
studies, it was reported that FGF-2 promoted the proliferation 
of hPDLCs in a dose-dependent manner and that the action 
plateaued at 10 ng/ml and decreased at >100 ng/ml, whereas 
ALP activities of hPDLCs were completely prohibited when 
the cells were treated with >10 ng/ml of FGF-2. The present 
data indicated that FGF‑2 inhibited calcified nodule forma-
tion; however, it did not affect the ALP activity of hPDLCs. 
This difference may be associated with the concentration of 
FGF-2 and the experimental conditions.
Endogenous Runx2 is expressed in pre‑osteoblasts, imma-
ture osteoblasts, early mature osteoblasts and pre‑odontoblasts, 
and has been  served as  a master  regulator  in osteoblastic 
differentiation and bone formation (30). The present results 
showed that there was no observable effect of FGF‑2 on Runx2 
gene expression regardless of FGF-2-induced Runx2 protein 
expression on day 14. We hypothesize that this phenomenon 
Figure 4. Western blotting of Runx2 and osteocalcin  (OCN) expression 
in human periodontal  ligament cells (hPDLCs).  (A) In  the western blot-
ting assay, basic  fibroblast growth  factor  (FGF‑2)  enhanced  the Runx2 
expression at days 7 and 14 in the growth medium (GM). In the osteogenic 
medium (OM), the Runx2 protein level exhibited no clear changes at day 7; 
however, there was a significant enhancement at day 14. (B) The protein level 
of OCN showed no evident change at days 7 and 14 in the GM and the OM.
Figure 3. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis of osteogenic and fibroblastic differentiation markers in human 
periodontal ligament cells (hPDLCs). The results are standardized to the reference gene GAPDH, and expressed as relative mRNA levels. (A) Runx2 mRNA. 
In the cultures lacking osteogenic inducers [growth medium (GM)], the Runx2 mRNA expression was upregulated significantly at days 7 and 14. However, in 
the osteogenic medium (OM), there were no clear trends in the levels of Runx2. (B) Collagen type Ⅰ, α1 (Col1a1) mRNA. In the GM, that is, in the absence of 
osteogenic inducers, basic fibroblast growth factor (FGF‑2) suppressed Col1a1 mRNA levels; however, no no significant effect was shown in the OM (in the 
presence of osteogenic inducers). (C) Osteocalcin (OCN) mRNA. In the GM, lacking osteogenic inducers, FGF-2 upregulated the gene expression of OCN 
significantly at day 7. However, in the OM supplemented with osteogenic inducers, there were no clear trends. (D) Epidermal growth factor receptor (EGFR) 
mRNA. FGF-2 promoted the expression of the EGFR gene in the absence of osteogenic inducers; however, there was inhibited EGFR gene expression in the 
presence of osteogenic inducers.
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may be explained by the study of Shui et al (31), which reported 
that osteoblastic differentiation of human mesenchymal stem 
cells (hMSCs) is associated primarily with increases of Runx2 






of extracellular matrix protein genes, which results in down-
regulation of Col1a1 mRNA (30,33).  In  the present  study, 
FGF‑2  inhibited Col1a1 mRNA levels to various degrees 
in the absence of osteogenic inducers. These results may be 
associated with the increase of Runx2 mRNA and protein 
expression triggered by FGF‑2 and are similar to previously 
reported studies, which identified that the addition of FGF‑2 to 





to inhibit the expression of Col1a1 mRNA in immortalized 
hMSCs during osteogenic differentiation  (36). This  func-
tion-suppressing differentiation of hPDLCs into mineralized 
tissue may aid in the stabilization of the fibroblastic phenotype 
and maintenance of hPDL structural integrity.
EGFR is highly upregulated in periodontal disease and 
may have a pivotal role in regulating cell migration, prolif-
eration and epithelial wound healing (37,38). A previous study 
has reported that the EGF/EGFR system regulates the pheno-
type of different cell populations (39), and pre‑osteoblasts 
and prechondrocytes have high levels of EGFR in vivo. 
However, the amount diminishes significantly as differentia-
tion progresses. Mature osteoblasts and chondrocytes do not 
express EGFR (40,41), and in addition, EGFR on hPDLCs 
functions as a negative regulator of their differentiation into 
mineralized tissue-forming cells (12). In the present study, 
the gene expression of EGFR was significantly upregulated 
by FGF‑2 and osteogenic inducers compared with hPDLCs 
cultured in the GM, but downregulated by FGF‑2 in the pres-
ence of osteogenic inducers. Thus, we hypothesize that the 
upregulation of the EGFR gene may have an important role in 
maintaining the hPDLC phenotype, balancing the population 
of fibroblasts in the hPDL by inhibiting their differentiation 
into mineralized tissue-forming cells.
In conclusion, the results of the present study demonstrate 
that FGF-2 facilitates hPDLC proliferation in the absence and 
presence of osteogenic inducers, while modulating the balance 
between  their  osteoblastic  and  fibroblastic  phenotypes  by 
affecting the gene expression of Runx2, OCN, Col1a1 and EGFR 
in the absence of ostoegenic inducers, in addition to inhibiting 
the mineralization of hPDLCs in the presence of osteogenic 





INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  46:  705-711,  2015 711
inducers. These results suggested that FGF-2 induces the 
growth of immature hPDLCs, which is a competitive inhibitor 
of epithelial downgrowth, and suppresses their differentiation 
into mineralized tissue by affecting Runx2 expression. This 
may lead to the acceleration of periodontal regeneration.
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